Expression of P-glycoprotein and CYP3A4 along the porcine oral-gastrointestinal tract: Implications on oral mucosal drug delivery

Drug Development and Industrial Pharmacy

Volumn 40, Issue 5, 2014, Pages 599-603

  Gao, Xiaoling ^a,b   Bhattacharya, Shiladitya ^a   Chan, William K ^a   Jasti, Bhaskara R ^a   Upadrashta, Bala ^a   Li, Xiaoling ^a  

^a UNIVERSITY OF THE PACIFIC   (United States)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Buccal mucosa; CYP3A4; Expression; P glycoprotein; Sublingual mucosa

Indexed keywords

CYTOCHROME P450 3A4; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN; CYTOCHROME P450 3A;

ARTICLE; CHEEK MUCOSA; COLON; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; ESOPHAGUS MUCOSA; GASTROINTESTINAL TRACT; ILEUM; JEJUNUM; MOUTH MUCOSA; NONHUMAN; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SWINE; WESTERN BLOTTING; ANIMAL; ANIMAL MODEL; BUCCAL DRUG ADMINISTRATION; GASTROINTESTINAL ABSORPTION; GENETICS; INTESTINE; METABOLISM; PIG; TISSUE DISTRIBUTION;

ADMINISTRATION, BUCCAL; ANIMALS; CYTOCHROME P-450 CYP3A; GASTROINTESTINAL TRACT; INTESTINES; MODELS, ANIMAL; MOUTH MUCOSA; ORAL MUCOSAL ABSORPTION; P-GLYCOPROTEIN; RNA, MESSENGER; SUS SCROFA; TISSUE DISTRIBUTION;

EID: 84898630367     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2014.884118     Document Type: Article

References (34)

1. Ueda K, Cornwell MM, Gottesman MM, et al. The mdr1 gene, responsible for multidrug-resistance, codes for P-glycoprotein. Biochem Biophys Res Commun 1986;141:956-62
2. Willingham MC, Cornwell MM, Cardarelli CO, et al. Single cell analysis of daunomycin uptake and efflux in multidrug-resistant and-sensitive KB cells: Effects of verapamil and other drugs. Cancer Res 1986;46:5941-6
3. Thiebaut F, Tsuruo T, Hamada H, et al. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci U S A 1987;84:7735-8
4. Greiner B, Eichelbaum M, Fritz P, et al. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest 1999;104:147-53
5. Gramatte T, Oertel R, Terhaag B, Kirch W. Direct demonstration of small intestinal secretion and site-dependent absorption of the betablocker talinolol in humans. Clin Pharmacol Ther 1996;59:541-9
6. Chiou WL, Chung SM, Wu TC, Ma C. A comprehensive account on the role of efflux transporters in the gastrointestinal absorption of 13 commonly used substrate drugs in humans. Int J Clin Pharmacol Ther 2001;39:93-101
7. Igel S, Drescher S, Murdter T, et al. Increased absorption of digoxin from the human jejunum due to inhibition of intestinal transportermediated efflux. Clin Pharmacokinet 2007;46:777-85
8. Woo JS, Lee CH, Shim CK, Hwang SJ. Enhanced oral bioavailability of paclitaxel by coadministration of the P-glycoprotein inhibitor KR30031. Pharm Res 2003;20:24-30
9. Schwarz UI, Gramatte T, Krappweis J, et al. P-glycoprotein inhibitor erythromycin increases oral bioavailability of talinolol in humans. Int J Clin Pharmacol Ther 2000;38:161-7
10. Guengerich FP, Mason PS. Immunological comparison of hepatic and extrahepatic cytochromes P-450. Mol Pharmacol 1979;15: 154-64
11. Zhang QY, Dunbar D, Ostrowska A, et al. Characterization of human small intestinal cytochromes P-450. Drug Metab Dispos 1999;27:804-9
12. Kato M. Intestinal first-pass metabolism of CYP3A4 substrates. Drug Metab Pharmacokinet 2008;23:87-94
13. Wacher VJ, Wu CY, Benet LZ. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: Implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog 1995;13:129-34
14. Kivisto KT, Niemi M, Fromm MF. Functional interaction of intestinal CYP3A4 and P-glycoprotein. Fundam Clin Pharmacol 2004;18:621-6
15. Wacher VJ, Salphati L, Benet LZ. Active secretion and enterocytic drug metabolism barriers to drug absorption. Adv Drug Deliv Rev 2001;46:89-102
16. Mouly S, Paine MF. P-glycoprotein increases from proximal to distal regions of human small intestine. Pharm Res 2003;20:1595-9
17. Zhang H, Zhang J, Streisand JB. Oral mucosal drug delivery: Clinical pharmacokinetics and therapeutic applications. Clin Pharmacokinet 2002;41:661-80
18. Vondracek M, Xi Z, Larsson P, et al. Cytochrome P450 expression and related metabolism in human buccal mucosa. Carcinogenesis 2001;22:481-8
19. Kragelund C, Hansen C, Torpet LA, et al. Expression of two drugmetabolizing cytochrome P450-enzymes in human salivary glands. Oral Dis 2008;14:533-40
20. Vondracek M, Weaver DA, Sarang Z, et al. Transcript profiling of enzymes involved in detoxification of xenobiotics and reactive oxygen in human normal and simian virus 40 T antigenimmortalized oral keratinocytes. Int J Cancer 2002;99:776-82
21. Lesch CA, Squier CA, Cruchley A, et al. The permeability of human oral mucosa and skin to water. J Dent Res 1989;68:1345-9
22. De Caro V, Giandalia G, Siragusa MG, et al. Evaluation of galantamine transbuccal absorption by reconstituted human oral epithelium and porcine tissue as buccal mucosa models: Part I. Eur J Pharm Biopharm 2008;70:869-73
23. Kulkarni U, Mahalingam R, Pather SI, et al. Porcine buccal mucosa as an in vitro model: Relative contribution of epithelium and connective tissue as permeability barriers. J Pharm Sci 2009;98:471-83
24. Chetty DJ, Chen LL, Chien YW. Characterization of captopril sublingual permeation: Determination of preferred routes and mechanisms. J Pharm Sci 2001;90:1868-77
25. Rodrigo MC, Martin DS, Redetzke RA, Eyster KM. A method for the extraction of high-quality RNA and protein from single small samples of arteries and veins preserved in RNAlater. J Pharmacol Toxicol Methods 2002;47:87-92
26. Luu TC, Bhattacharya P, Chan WK. Cyclophilin-40 has a cellular role in the aryl hydrocarbon receptor signaling. FEBS Lett 2008; 582:3167-73
27. Berggren S, Gall C, Wollnitz N, et al. Gene and protein expression of P-glycoprotein, MRP1, MRP2, and CYP3A4 in the small and large human intestine. Mol Pharm 2007;4:252-7
28. Taipalensuu J, Tavelin S, Lazorova L, et al. Exploring the quantitative relationship between the level of MDR1 transcript, protein and function using digoxin as a marker of MDR1-dependent drug efflux activity. Eur J Pharm Sci 2004;21:69-75
29. Woodahl EL, Ho RJ. The role of MDR1 genetic polymorphisms in interindividual variability in P-glycoprotein expression and function. Curr Drug Metab 2004;5:11-19
30. Pal D, Mitra AK. MDR-And CYP3A4-mediated drug-drug interactions. J Neuroimmune Pharmacol 2006;1:323-39
31. Zhou SF, Lai X. An update on clinical drug interactions with the herbal antidepressant St. John's wort. Curr Drug Metab 2008;9: 394-409
32. Thummel KE, O'Shea D, Paine MF, et al. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3Amediated metabolism. Clin Pharmacol Ther 1996;59:491-502
33. Thorn M, Finnstrom N, Lundgren S, et al. Cytochromes P450 and MDR1 mRNA expression along the human gastrointestinal tract. Br J Clin Pharmacol 2005;60:54-60
34. von Richter O, Burk O, Fromm MF, et al. Cytochrome P450 3A4 and P-glycoprotein expression in human small intestinal enterocytes and hepatocytes: A comparative analysis in paired tissue specimens. Clin Pharmacol Ther 2004;75:172-83